EPISODE · Jun 8, 2026 · 11 MIN
Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data
from The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 minus · host BZ Group
Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refractory migraine. Plus Otsuka Voyxact IgAN data, Replimune's third RP1 submission, the Supreme Court's skinny label ruling, and Biogen's salanersen Breakthrough Therapy Designation.
What this episode covers
Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refractory migraine. Plus Otsuka Voyxact IgAN data, Replimune's third RP1 submission, the Supreme Court's skinny label ruling, and Biogen's salanersen Breakthrough Therapy Designation.
NOW PLAYING
Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m